秦天星等
[摘要] 目的： 探讨解郁安神汤合并利培酮治疗慢性精神分(fēn)裂症的疗效和安全性。方法： 将100例慢性精神分(fēn)裂症患者随机分(fēn)為(wèi)研究组（解郁安神汤合并利培酮治疗）和对照组（单用(yòng)利培酮治疗）各50例，观察时间12周，用(yòng)阳性和阴性综合征量表（PANSS）和副反应量表（TESS）评定疗效和安全性。 结果：治疗12周后，研究组显效率和有(yǒu)效率均高于对照组，PANSS评分(fēn)较治疗前显著下降且低于同期对照组，P<0.05~0.01，但TESS评分(fēn)同期比较2组间差异无统计學(xué)意义，P>0.05。 结论：解郁安神汤合并利培酮治疗慢性精神分(fēn)裂症有(yǒu)确切的疗效且优于单用(yòng)利培酮治疗，不增加不良反应，临床使用(yòng)安全。
[关键词] 解郁安神汤；利培酮； 精神分(fēn)裂症；疗效；安全性
Efficacy and safety of Jieyu’anshentang combined with resperidone
in treatment of the chronic schizophrenia
Qin Tian-xing, Guo Xi-xian, Zeng De-zhi, et al.
（The Ningbo Psychiatric Hospital，Ningbo Zhejiang 315032,China）
[Abstract]Objective:To explore efficacy and safety of Jieyu’anshentang combined with resperidone in treatment of the chronic schizophrenia.Methods: All 100 chronic patients with schizophrenia diagnosed according to CCMD-3 criteria were randomly assigned to study groups (treated with Jieyu’anshentang combined with resperidone) and control group (treated with resperidone alone) for 12 weeks. Each had 50 cases.The Positive and Negative Syndrome Scale(PANSS) and Treatment Emergent Side effect Scale(TESS) were used to evaluate the efficacy and adverse effect respectively. Results: After 12weeks, the clinical efficacy in the study group was significantly better than that in the control group. The scores of PANSS in the study group were lower significantly than those in the control group and after 4 weeks. So as before treatment. But The incidence of adverse effect had no significant difference between the two groups. Conclusion:Jieyu’anshentang combined with resperidone is more effective than resperidone alone in treatment of the chronic schizophrenia. It is the same safe as resperidone.
[Key words] Jieyu’anshentan Resperidone Schizophrenia Efficacy Safety
